GlassScriptPhysician profile
Divyang Sorathia
NPI 1194932897
$19,202.10
in general payments reported to CMS, 2019-2025
41 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $214 · 2021: $326 · 2022: $1,033 · 2023: $12K · 2024: $2,428 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,374 · Food and Beverage: $6,223 · Travel and Lodging: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,374.02 |
| Food and Beverage | $6,222.52 |
| Travel and Lodging | $770.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,152.62 | 2023-2024 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $2,153.98 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,203.37 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Olympus Corporation of The Americas | $673.46 | 2019 | |
| Jazz Pharmaceuticals INC. | $638.95 | 2020-2025 | |
| Insmed, INC. | $449.19 | 2019-2025 | Arikayce |
| Mallinckrodt Hospital Products INC. | $349.48 | 2022-2025 | Acthar |
| United Therapeutics Corporation | $337.79 | 2022-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.15 | 2019-2025 | Ofev, Jascayd |
| Inspire Medical Systems, INC. | $296.58 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $276.37 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $253.36 | 2021-2025 | Glassia |
| Mylan Specialty L.P. | $238.55 | 2019-2023 | Yupelri |
| Grifols USA, LLC | $198.00 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $162.85 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $153.55 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $152.35 | 2023 | Opsumit, Uptravi |
| Genzyme Corporation | $150.06 | 2023-2025 | |
| Amgen INC. | $136.36 | 2022-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $98.03 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Olympus America INC. | $82.05 | 2021 | |
| Philips North America LLC | $65.00 | 2024 | (Ae4) Secretion Management |
| Phadia US INC. | $59.11 | 2021-2024 | Immunocap |
| Axsome Therapeutics, INC. | $57.86 | 2023-2025 | Sunosi |
| Inogen, INC. | $55.96 | 2024-2025 | |
| Genentech USA, INC. | $55.31 | 2022 | |
| Harmony Biosciences LLC | $55.15 | 2020-2024 | |
| Vapotherm INC | $39.49 | 2022-2023 | Vapotherm |
| Lilly USA, LLC | $27.79 | 2025 | Zepbound |
| Advanced Respiratory, INC | $27.53 | 2019 | |
| Circassia INC. | $26.97 | 2019-2020 | |
| Abbvie INC. | $26.28 | 2022 | |
| Pharming Healthcare, INC. | $26.25 | 2022 | |
| Resmed Corp | $25.34 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.91 | 2022 | |
| Verona Pharma, INC. | $19.52 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $19.35 | 2024 | Lumryz |
| Merck Sharp & Dohme LLC | $17.33 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.16 | 2023 | Nuzyra |
| Ambu INC. | $7.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divyang Sorathia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.